Literature DB >> 25752320

Supraspinal actions of nociceptin/orphanin FQ, morphine and substance P in regulating pain and itch in non-human primates.

H Ding1, K Hayashida2, T Suto2, D D Sukhtankar1, M Kimura2, V Mendenhall3, M C Ko1,4,5.   

Abstract

BACKGROUND AND
PURPOSE: Nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor agonists display a promising analgesic profile in preclinical studies. However, supraspinal N/OFQ produced hyperalgesia in rodents and such effects have not been addressed in primates. Thus, the aim of this study was to investigate the effects of centrally administered ligands on regulating pain and itch in non-human primates. In particular, nociceptive thresholds affected by intracisternal N/OFQ were compared with those of morphine and substance P, known to provide analgesia and mediate hyperalgesia, respectively, in humans. EXPERIMENTAL APPROACH: Intrathecal catheters were installed to allow intracisternal and lumbar intrathecal administration in awake and unanaesthetized rhesus monkeys. Nociceptive responses were measured using the warm water tail-withdrawal assay. Itch scratching responses were scored from videotapes recording behavioural activities of monkeys in their home cages. Antagonist studies were conducted to validate the receptor mechanisms underlying intracisternally elicited behavioural responses. KEY
RESULTS: Intracisternal morphine (100 nmol) elicited more head scratches than those after intrathecal morphine. Distinct dermatomal scratching locations between the two routes suggest a corresponding activation of supraspinal and spinal μ receptors. Unlike intracisternal substance P, which induced hyperalgesia, intracisternal N/OFQ (100 nmol) produced antinociceptive effects mediated by NOP receptors. Neither peptide increased scratching responses. CONCLUSIONS AND IMPLICATIONS: Taken together, these results demonstrated differential actions of ligands in the primate supraspinal region in regulating pain and itch. This study not only improves scientific understanding of the N/OFQ-NOP receptor system in pain processing but also supports the therapeutic potential of NOP-related ligands as analgesics.
© 2015 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25752320      PMCID: PMC4500367          DOI: 10.1111/bph.13124

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  60 in total

Review 1.  An evidence-based approach to human dermatomes.

Authors:  M W L Lee; R W McPhee; M D Stringer
Journal:  Clin Anat       Date:  2008-07       Impact factor: 2.414

2.  Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study.

Authors:  D Peckys; G B Landwehrmeyer
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

3.  Effects of intrathecally administered nociceptin/orphanin FQ in monkeys: behavioral and mass spectrometric studies.

Authors:  M C Holden Ko; Hui Wei; James H Woods; Robert T Kennedy
Journal:  J Pharmacol Exp Ther       Date:  2006-06-09       Impact factor: 4.030

4.  Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with (125)I-[(14)Tyr]-orphanin FQ binding.

Authors:  C R Neal; A Mansour; R Reinscheid; H P Nothacker; O Civelli; H Akil; S J Watson
Journal:  J Comp Neurol       Date:  1999-10-04       Impact factor: 3.215

5.  Antinociceptive effects of nociceptin/orphanin FQ administered intrathecally in monkeys.

Authors:  Mei-Chuan Ko; Norah N Naughton
Journal:  J Pain       Date:  2009-02-23       Impact factor: 5.820

Review 6.  Pathophysiology and management of opioid-induced pruritus.

Authors:  Arjunan Ganesh; Lynne G Maxwell
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential.

Authors:  David G Lambert
Journal:  Nat Rev Drug Discov       Date:  2008-08       Impact factor: 84.694

8.  Roles for substance P and gastrin-releasing peptide as neurotransmitters released by primary afferent pruriceptors.

Authors:  Tasuku Akiyama; Mitsutoshi Tominaga; Auva Davoodi; Masaki Nagamine; Kevin Blansit; Alexander Horwitz; Mirela Iodi Carstens; E Carstens
Journal:  J Neurophysiol       Date:  2012-11-14       Impact factor: 2.714

9.  Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys.

Authors:  Mei-Chuan Ko; James H Woods; William E Fantegrossi; Chad M Galuska; Jürgen Wichmann; Eric P Prinssen
Journal:  Neuropsychopharmacology       Date:  2009-03-11       Impact factor: 7.853

Review 10.  Prophylaxis and treatment of the side-effects of neuraxial morphine analgesia following cesarean delivery.

Authors:  Jennifer E Dominguez; Ashraf S Habib
Journal:  Curr Opin Anaesthesiol       Date:  2013-06       Impact factor: 2.706

View more
  25 in total

Review 1.  Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.

Authors:  Nurulain T Zaveri
Journal:  J Med Chem       Date:  2016-03-14       Impact factor: 7.446

2.  Anti-PD-1 treatment impairs opioid antinociception in rodents and nonhuman primates.

Authors:  Zilong Wang; Changyu Jiang; Qianru He; Megumi Matsuda; Qingjian Han; Kaiyuan Wang; Sangsu Bang; Huiping Ding; Mei-Chuan Ko; Ru-Rong Ji
Journal:  Sci Transl Med       Date:  2020-02-19       Impact factor: 17.956

3.  BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates.

Authors:  Norikazu Kiguchi; Huiping Ding; Gerta Cami-Kobeci; Devki D Sukhtankar; Paul W Czoty; Heather B DeLoid; Fang-Chi Hsu; Lawrence Toll; Stephen M Husbands; Mei-Chuan Ko
Journal:  Br J Anaesth       Date:  2019-03-01       Impact factor: 9.166

4.  A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates.

Authors:  Huiping Ding; Norikazu Kiguchi; Dennis Yasuda; Pankaj R Daga; Willma E Polgar; James J Lu; Paul W Czoty; Shiroh Kishioka; Nurulain T Zaveri; Mei-Chuan Ko
Journal:  Sci Transl Med       Date:  2018-08-29       Impact factor: 17.956

5.  Spinal antinociceptive effects of the novel NOP receptor agonist PWT2-nociceptin/orphanin FQ in mice and monkeys.

Authors:  A Rizzi; D D Sukhtankar; H Ding; K Hayashida; C Ruzza; R Guerrini; G Calò; M C Ko
Journal:  Br J Pharmacol       Date:  2015-05-12       Impact factor: 8.739

Review 6.  Central N/OFQ-NOP Receptor System in Pain Modulation.

Authors:  Norikazu Kiguchi; Huiping Ding; Mei-Chuan Ko
Journal:  Adv Pharmacol       Date:  2015-12-17

7.  A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates.

Authors:  Huiping Ding; Paul W Czoty; Norikazu Kiguchi; Gerta Cami-Kobeci; Devki D Sukhtankar; Michael A Nader; Stephen M Husbands; Mei-Chuan Ko
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-29       Impact factor: 11.205

8.  Antinociceptive, reinforcing, and pruritic effects of the G-protein signalling-biased mu opioid receptor agonist PZM21 in non-human primates.

Authors:  Huiping Ding; Norikazu Kiguchi; David A Perrey; Thuy Nguyen; Paul W Czoty; Fang-Chi Hsu; Yanan Zhang; Mei-Chuan Ko
Journal:  Br J Anaesth       Date:  2020-08-17       Impact factor: 9.166

9.  Altered expression of glial markers, chemokines, and opioid receptors in the spinal cord of type 2 diabetic monkeys.

Authors:  Norikazu Kiguchi; Huiping Ding; Christopher M Peters; Nancy D Kock; Shiroh Kishioka; J Mark Cline; Janice D Wagner; Mei-Chuan Ko
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2016-10-14       Impact factor: 5.187

Review 10.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.